Pedigrees of the 13 families included in the study.

<p>Circles represent females and squares are males. Filled circles are classified as affected with CDGP, while shaded circles are unknown or do not fulfill the criteria for CDGP. The proband from each family is marked with an arrow. Individuals with an asterisk (*) have been sequenced at the pericentromere of chr 2. All probands and both of their parents were genotyped (denoted with the symbol #) except family 11, in which only the proband and affected parent were genotyped.</p

Multidimensional scaling (MDS) plots.

<p>Each point represents an individual genome. Red triangles are individuals from the Kuopio region of Finland while violet triangles are individuals from Helsinki. Each blue circle represents a proband from each of the 13 CDGP families. The yellow circle is the proband from Family 1. Panel A shows the relationship between principal components (PCs) 1 and 2, which explain most of the genetic variation. Panel B shows PC1 versus PC3, which appear to mimic a geographical northeast to southwest axis.</p

A Description of the FINRISK 1992 and 1997 Cohorts

<p>Compared to FINRISK-92, the FINRISK-97 cohort includes an additional sample of individuals aged 65–74 y. Numbers for this additional sample are described at the right-hand side for each endpoint. Persons examined refers to cohort individuals for whom information on smoking, blood pressure, cholesterol, and DNA, as well as consent for the use of DNA to study CHD and stroke, were available. Subcohorts are stratified random samples of the original cohorts including also cases. Mortality cases show total mortality, including also those who died from CHD or stroke. Thus, numbers in the boxes of subcohorts and outcome events are not mutually exclusive (see <a href="http://www.plosgenetics.org/article/info:doi/10.1371/journal.pgen.0020069#pgen-0020069-t001" target="_blank">Table 1</a>). F, females; M, males.</p